Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

Keflex Product Sales Grow to $10.5 Million in 2007; MOXATAG, Company's Lead PULSYS Product, Approved Following Year-end; Process to Explore Strategic

Alternatives Ongoing

GERMANTOWN, Md., March 4 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced financial and operational results for the quarter and fiscal year ended December 31, 2007.

MiddleBrook reported fourth quarter 2007 revenue of $2.9 million, compared to revenue of $3.1 million in the third quarter of 2007 and $1.2 million in the fourth quarter of 2006. Revenue for the full year of 2007 increased to $10.5 million, up 117% from revenue of $4.8 million for the full year of 2006.

MiddleBrook reported research and development (R&D) expenses in the fourth quarter of $3.5 million, down from third quarter 2007 R&D expenses of $5.5 million and fourth quarter 2006 R&D expenses of $6.3 million. For the full year of 2007, R&D expenses declined to $22.0 million, from $26.0 million in R&D expenses for the full year of 2006.

Total operating expenses for the fourth quarter of 2007 were $9.8 million, down from $13.2 million in the third quarter of 2007 and $14.9 million in the fourth quarter of 2006. However, total expenses for the full year of 2007 increased slightly to $50.6 million, compared to total expenses of $48.2 million in 2006.

Net loss was $9.1 million for the fourth quarter, compared to a net loss of $10.1 million in the third quarter of 2007 and a net loss of $13.8 million in the fourth quarter of 2006. Net loss for the full year of 2007 was $42.2 million, compared to a net loss of $42.
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... assessment to be added to the, ... 28 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or "Company") ... on activities as well as an interim progress ... is conducting a human Phase 1b/2a clinical trial ...
... Sigma-Aldrich (Nasdaq: SIAL ) today announced the global ... provides a novel and powerful approach to RNAi screening in ... http://www.sigma.com/esirna ) incorporates a pool of hundreds of ... designed to eliminate the trial and error approach of identifying ...
... Techne Corporation,s (Nasdaq: TECH ) consolidated net ... to $27.6 million or $.74 per diluted share compared with ... ended March 31, 2008. For the nine months ended ... $79.9 million or $2.10 per diluted share compared with $76.3 ...
Cached Biology Technology:Resverlogix Provides Quarterly Update 2Resverlogix Provides Quarterly Update 3Resverlogix Provides Quarterly Update 4Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 2Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 3Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 7
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... clever trick for overcoming sleep deprivation. Sam Ridgway from the ... to send half of their brains to sleep while the ... to be able to remain continually vigilant for sounds for ... colleagues from San Diego and Tel Aviv wonder whether the ...
... May 1, 2009 As people become more educated, studies ... lower in calories but higher in nutrients. They also pay ... of the Journal of the American Dietetic Association , ... and food costs of a sample of 164 adults in ...
... plants are constantly confronted with adverse environmental conditions, lowering ... use specialized signals, called stress hormones, to sense difficult ... Of the various stress hormones, abscisic acid ... last 30 years as the key hormone that helps ...
Cached Biology News:Dolphins maintain round-the-clock visual vigilance 2People of higher socioeconomic status choose better diets -- but pay more per calorie 2Synthetic chemical offers solution for crops facing drought 2Synthetic chemical offers solution for crops facing drought 3
Request Info...
Request Info...
... ml CELLection Dynabeads (4.5 m) coated with ... antigen EpCAM and DNase Releasing Buffer. ... epithelial tumour cells directly from blood, bone ... be enriched from bone marrow. Enriched cells ...
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: